Please login to the form below

Not currently logged in
Email:
Password:

Hookipa Biotech appoints new global head of research and development

Dr Igor Matushansky joins the firm from Daiichi Sankyo

Dr Igor Matushansky

Hookipa Biotech has appointed Dr Igor Matushansky as its global head, research and development in a role that focuses on strategic priorities.

Previously global head of translational development for oncology at Daiichi Sankyo, Matushansky has experience in early oncology therapeutic programmes, strategy and development.

He said: “It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”

Matushansky has also previously worked for Novartis’ oncology translational medicine unit as clinical programme lead.

Joern Aldag, CEO at Hookipa Biotech, said: “Dr Matushansky’s valuable experience heading up R&D units at big pharma companies coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our company from prophylactic to therapeutic immuno-oncology focused therapies.

“I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”

22nd March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics